Inhibition of nuclear factor-κB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells

Melanoma Research

Volumn 14, Issue 3, 2004, Pages 165-171

  Zheng, Mingzhong ^a   Ekmekcioglu, Suhendan ^a   Walch, Eugene T ^a   Tang, Chi Hui ^a   Grimm, Elizabeth A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Cell cycle; Curcumin; Inducible nitric oxide synthase; Melanoma; Nuclear factor B

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 2; CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROTEIN KINASE; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; METAPHASE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ACTIVE TRANSPORT, CELL NUCLEUS; APOPTOSIS; CASPASE 3; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CURCUMIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; G2 PHASE; HUMANS; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042788374     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000129374.76399.19     Document Type: Article

References (35)

1. Karin M, Lin A. NF-kappa B at the crossroads of life and death. Nat Immunol 2002; 3:221-227.
2. Richmond A. NF-kappa B, chemokine gene transcription and tumour growth. Nat Rev Cancer 2002; 2:1-11.
3. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270:24995-25000.
4. Chan MM, Huang HI, Fenton MR, Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 1998; 55:1955-1962.
5. Sreejayan N, Rao MNA. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 1997; 49:105-107.
6. Bush JA, Cheung KJ, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001; 271:305-314.
7. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogens 2001; 20:7597-7609.
8. Dodd F, Limoges M, Boudreau RT, Rowden G, Murphy PR, Too CK. L-Arginine inhibits apoptosis via a NO-dependent mechanism in Nb2 lymphoma cells. J Cell Biochem 2000; 77:624-634.
9. Zhang XM, Xu Q. Metastatic melanoma cells escape from immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of immunocytes. Melanoma Res 2001; 11:559-567.
10. Mehta K, Pantazis P, McQueen T, Aggarwal BB. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 1997; 8:470-481.
11. Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A. Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. Cancer Res 2001; 61:3682-3688.
12. Weller R, Billiar T, Vodovotz Y. Pro- and anti-apoptotic effects of nitric oxide in irradiated keratinocytes: the role of superoxide. Skin Pharmacol Appl Skin Physiol 2002; 15:348-352.
13. Fiorucci S, Mencarelli A, Mannucci R, Distrutti E, Morelli A, del Soldato P, Moncada S. NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. FASEB J 2002; 16:1645-1647.
14. Tang ZL, Wasserloos KJ, Liu X, Stitt MS, Reynolds IJ, Pitt BR, St Croix CM. Nitric oxide decreases the sensitivity of pulmonary endothelial cells to LPS-induced apoptosis in a zinc-dependent fashion. Mol Cell Biochem 2002; 234-235:211-217.
15. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000; 6:4768-4775.
16. Xie K, Fidler IJ. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev 1998; 17:55-75.
17. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998; 19:711-721.
18. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18:7621-7636.
19. 1 cell-cycle arrest and apoptosis induced by terfenadine in human cancer cells. Mol Carcinog 2003; 37:39-50.
20. Jallepalli PV, Lengauer C, Vogelstein B, Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 2003; 278:20475-20479.
21. Kim SH, Um JH, Dong-Won B, Kwon BH, Kim DW, Chung BS, Kang CD. Potentiation of chemosensitivity in multidrug-resistant human leukemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin. Leuk Res 2000; 11:917-925.
22. Chang JY, Chavis JA, Liu LZ, Drew PD. Cholesterol oxides induce programmed cell death in microglial cells. Biochem Biophys Res Commun 1998; 249:817-821.
23. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000; 165:5962-5969.
24. Kozlowska K, Cichorek M, Zarzeczna M. A study on nitric oxide secretion by transplantable melanoma cell lines with regard to their spontaneous apoptosis. Neoplasma 2001; 48:496-500.
25. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59:1391-1399.
26. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995; 7:547-553.
27. Faiola B, Bauer AK, Fuller ES, Wong VA, Pluta LJ, Abernethy DJ, et al. Variations in Prkdc and susceptibility to benzene-induced toxicity in mice. Toxicol Sci 2003; 75:321-332.
28. Beck WT, Mullrt TJ, Tanzer LR. Altered surface membrane glycoprotein in vinca alkaloid-resistant human leukemic lymphoblast. Cancer Res 1976; 39:2070-2076.
29. Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 2002; 22:6521-6532.
30. Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000; 275:32592-32597.
31. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18:6853-6866.
32. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 1999; 59:4516-4518.
33. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5:828-831.
34. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138-3151.
35. Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. JBC 2004; 279:288-289.